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A B S T R A C T
Brugada syndrome predisposes to sudden death due to disruption of normal cardiac ion channel function, yet our
understanding of the underlying cellular mechanisms is incomplete. Commonly used heterologous expression
models lack many characteristics of native cardiomyocytes and, in particular, the individual genetic background
of a patient. Patient-speciﬁc induced pluripotent stem (iPS) cell-derived cardiomyocytes (iPS-CM) may uncover
cellular phenotypical characteristics not observed in heterologous models. Our objective was to determine the
properties of the sodium current in iPS-CM with a mutation in SCN5A associated with Brugada syndrome.
Dermal ﬁbroblasts from a Brugada syndrome patient with a mutation in SCN5A (c.1100G > A, leading to
Nav1.5_p.R367H) were reprogrammed to iPS cells. Clones were characterized and diﬀerentiated to form beating
clusters and sheets. Patient and control iPS-CM were structurally indistinguishable. Sodium current properties of
patient and control iPS-CM were compared. These results were contrasted with those obtained in tsA201 cells
heterologously expressing sodium channels with the same mutation.
Patient-derived iPS-CM showed a 33.1–45.5% reduction in INa density, a shift in both activation and in-
activation voltage-dependence curves, and faster recovery from inactivation. Co-expression of wild-type and
mutant channels in tsA201 cells did not compromise channel traﬃcking to the membrane, but resulted in a
reduction of 49.8% in sodium current density without aﬀecting any other parameters.
Cardiomyocytes derived from iPS cells from a Brugada syndrome patient with a mutation in SCN5A re-
capitulate the loss of function of sodium channel current associated with this syndrome; including pro-ar-
rhythmic changes in channel function not detected using conventional heterologous expression systems.
1. Introduction
Brugada syndrome is an autosomal dominant hereditary condition
that is responsible for 20% of sudden cardiac deaths of patients with
structurally normal hearts [1]. It is characterized by an abnormal
electrocardiogram with ST-segment elevation in the right precordial
leads V1 to V3 and right bundle-branch block frequently leading to
ventricular ﬁbrillation [2]. Patients often present symptoms of
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ventricular tachycardia, bradycardia, and atrial ventricular node con-
duction disorder, and more males than females are diagnosed with
Brugada syndrome. To date, the implantation of a cardioverter deﬁ-
brillator is the only proven eﬀective treatment of the disease [3,4].
Whilst Brugada syndrome has been associated with mutations in 23
genes [5], the majority of these disease-related mutations have been
found in SCN5A [6]. This gene encodes the alpha-subunit of the cardiac
sodium channel (Nav1.5) which is responsible for the sodium inward
current (INa). Heterologous expression of recombinant Nav1.5 channels
in conventional cellular systems has provided invaluable insight into
the molecular and electrophysiological basis of Brugada syndrome.
Still, the main limitation of this approach is that the cells typically used
(i.e., HEK293 cells, Xenopus oocytes) deviate considerably from human
cardiomyocytes in many relevant aspects. These cells do not reﬂect the
modulatory eﬀects of accessory channel subunits or the inﬂuence of
potential compensatory pathways, both of which could take place in
native cardiomyocytes. Thus, studies of mutant channels using such
expression systems might be missing important characteristics of native
cardiomyocytes relevant to pathophysiology.
The diﬀerentiation of induced pluripotent stem (iPS) cells from
patients with cardiac diseases into cardiomyocytes (iPS-CM) provides a
cell model highly homologous to native human cardiomyocytes. The
use of these surrogate cells allows investigators to study mutant ion
channels in their native patient-speciﬁc cell environment. This includes
all their regulatory proteins, and importantly, a physiologically con-
trolled level of protein expression. To date, several cardiac channelo-
pathies including long QT syndrome (LQT), catecholaminergic poly-
morphic ventricular tachycardia and Timothy syndrome have been
modeled using the iPS cell approach [7]. Likewise, Davis et al. used iPS-
CM to model an overlap LQT/Brugada syndrome [8]. Recently, BrS was
modeled using patient-speciﬁc iPS-CM [9]. However, to date no reports
exist that provide a complete characterization of the sodium current
properties in Brugada syndrome patient-speciﬁc iPS-CM.
We generated iPS-CM from a patient diagnosed with Brugada
Syndrome who carries a heterozygous missense mutation in SCN5A
(c.1100G > A, leading to Nav1.5_p.R367H). This mutation had been
previously found in Brugada Syndrome patients [10,11]. Moreover,
recombinant channels with this mutation were previously studied in
homozygosis in both HEK293 cells and Xenopus oocytes [10–14]. These
studies showed a total loss of function of the sodium current. Thus, we
expected that, in iPS-CM, the presence of the Nav1.5_p.R367H mutation
in heterozygosis would cause a decrease near 50% of the total current
due to the expression of non-functional channels translated from the
mutant allele. To assess this assumption, we analyzed and compared
sodium current properties of iPS-CM derived from the patient and from
a healthy individual without this mutation.
2. Materials and methods
Detailed experimental procedures are available in the Online Data
Supplement.
2.1. Isolation and reprogramming of ﬁbroblasts to induced pluripotent stem
(iPS) cells
This study was approved by the South East Scotland Research Ethics
Committee REC reference 11-SS-0095 and written informed consent
was obtained from the two subjects included in the study. Dermal
biopsies were dissected into 1 mm3 pieces, which were transferred to
culture plastic, covered with a glass coverslip and cultured for 2 weeks
before harvest. 5 × 105 ﬁbroblasts were reprogrammed with the
Addgene episomal vectors pCXLE-hOCT3/4-shp53-F (encoding for Oct4
and shp53, Addgene plasmid # 27077), pCXLE-hSK (Sox2 and Klf,
Addgene plasmid # 27078) and pCXLE-hUL (LMyc and Lin28, Addgene
plasmid # 27080). Reprogrammed ﬁbroblasts were replated onto 0.1%
gelatin and medium was changed to stem cell selection medium (TeSR-
E8, STEMCELL Technologies SARL, Grenoble, France) 7 days post
electroporation. Colonies appeared 15–20 days later. Individual clones
were picked into Matrigel (BD Biosciences, Franklin Lakes, NJ, USA)
coated tissue culture plates and maintained in TeSR-E8.
2.2. Sequencing
For all iPS cell lines, the whole coding region of SCN5A was am-
pliﬁed (Verities PCR, Applied Biosystems, Austin, TX, USA), the PCR
products were puriﬁed (ExoSAP-IT, Aﬀymetrix, Inc. USB® Products,
Cleveland, OH, USA) and they were directly sequenced in both direc-
tions (Big Dye Terminator v3.1 cycle sequencing kit and 3130XL
Genetic Analyzer, both from Applied Biosystems). DNA sequences ob-
tained were compared with SCN5A reference sequence NM_198056.2
using SeqScape v2.6 (Applied Biosystems).
2.3. Real-time quantitative reverse transcription PCR (qPCR)
RNA extraction and cDNA synthesis were carried out according to
manufacturer's speciﬁcations (Cambio, Cambridge, UK and Applied
Biosystems-Thermo Fisher Scientiﬁc). qPCR reactions were set up using
the GoTaq qPCR Master Mix kit (Promega, Madison, WI, USA), and
included a reference dye. The samples were analyzed in biological tri-
plicates using the primers listed in Supplemental Table 2 and run in a
Rotor-Gene 6000 (Corbett Life Science-Qiagen, Manchester, UK).
Expression levels were determined by the ΔΔCt method.
2.4. Flow cytometry
Undiﬀerentiated iPS cells were double stained with ﬂuorochrome-
conjugated antibodies against SSEA-3 (Alexa Fluor 488 conjugate,
BioLegend, San Diego, CA, USA) and SSEA-4 (Phycoerythrin conjugate,
BD Biosciences) for 30 min at room temperature. Samples were run on a
FACS Fortessa Flow Cytometry System acquiring a minimum of 10,000
events. Data was analyzed using FlowJo software (Treestar, Inc., San
Carlos, CA, USA).
2.5. Single nucleotide polymorphism (SNP) analysis
Genomic DNA was isolated from undiﬀerentiated iPS cells using the
MasterPure™ Complete DNA&RNA Puriﬁcation Kit (Cambio). Single
nucleotide polymorphism (SNP) analysis was performed by AROS
Applied Biotechnology A/S (Aarhus, Denmark) using the Illumina
CytoSNP-12 array. Data was visualized and analyzed using the
GenomeStudio V2011.1 software.
2.6. Diﬀerentiation
Embryoid bodies (EBs) were formed from conﬂuent undiﬀerentiated
iPS cell colonies. Collagenase treatment and mechanical disruption re-
sulted in roughly evenly sized clumps that were cultured in suspension
on non-treated tissue culture dishes in serum-supplemented medium for
7 days at 37 °C and 5% CO2. After a further 10 days on 0.1% gelatin
coated tissue culture dishes, EBs were ﬁxed and stained for the 3 germ
layers.
For guided cardiac diﬀerentiation, two diﬀerent protocols were
used. First, a modiﬁed version of a published protocol [15] was im-
plemented. In short, EBs were formed in supplemented Knock-out
Dulbecco's Modiﬁed Eagle Medium, and cultured for 4 days in sus-
pension and a further 10 days on 0.1% gelatin. Beating bodies started to
emerge around day 8 after EB formation. Beating bodies were dis-
aggregated using a previously published protocol [16,17].
The second protocol used was monolayer-based [18]. Brieﬂy, iPS
cells were allowed to grow to 85–90% conﬂuence. Then, culture media
was changed to diﬀerentiation medium containing CHIR99021 (Day 0).
Twenty-four hours later, media was changed to diﬀerentiation medium
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with heparin. From day 2 to day 5 the media contained both heparin
and IWP2, and was renewed daily. At day 6, media was changed to
diﬀerentiation medium with heparin only. The day after, the diﬀer-
entiation medium contained heparin and insulin. From day 8 onwards,
cells were fed diﬀerentiation medium with insulin, and media was re-
newed every 2 days. iPS-CM started beating around day 8–10. iPS-CM
monolayers were disaggregated with 0.25% trypsin-EDTA.
2.7. Immunocytochemistry
Undiﬀerentiated cells were ﬁxed in 4% paraformaldehyde for
10 min, permeabilized with 0.1% Triton X-100, blocked in 3% horse
serum and stained for Nanog (R &D Systems, Abingdon, UK), Oct3/4
and Tra-1-60 (both from SantaCruz Biotechnology, Dallas, TX, USA).
EBs diﬀerentiated to the three germ layers were ﬁxed in cold methanol,
permeabilized and blocked with 10% goat serum and stained for α-
fetoprotein, β-tubulin III (both from Sigma-Aldrich, St. Louis, MO, USA)
and Muscle actin (Dako, Glostrup, Denmark). Disaggregated beating
bodies were ﬁxed in 4% paraformaldehyde, permeabilized with 0.5%
Triton X-100, blocked in 3% goat serum and stained for cardiac tro-
ponin T, cardiac troponin I, and alpha actinin (all from Abcam,
Cambridge, UK). Appropriate secondary antibodies were used and cells
were counterstained and mounted with ProLong Gold Antifade Reagent
with DAPI.
2.8. Transmission electron microscopy (TEM)
Beating bodies were ﬁxed in 2.5% glutaraldehyde in 4% PFA, wa-
shed with 0.1 mol/L Phosphate buﬀer, post-ﬁxed in 1% Osmium
Tetroxide in 0.1 mol/L Phosphate buﬀer, then washed with 0.1 mol/L
Phosphate buﬀer. Samples were dehydrated in 50%, 70%, 90% and
100% ethanol, then in propylene oxide, and embedded in Araldite
resin. Sections, 1 μm thick, were cut on a Reichert OMU4 ultra-
microtome, stained with Toluidine Blue, and viewed in a light micro-
scope to select suitable areas for investigation. Ultrathin sections,
60 nm thick, were cut from selected areas, stained in Uranyl Acetate
and Lead Citrate then viewed in a Philips CM120 Transmission electron
microscope. Images were taken on a Gatan Orius CCD camera.
2.9. Sodium current recordings in iPS-CM
Beating bodies and monolayers were disaggregated and plated onto
1% gelatin. Whole cell sodium currents were measured at room tem-
perature either using the perforated patch-clamp technique 24–48 h
after disaggregation (for beating bodies) or using the whole cell tech-
nique 24-96 h after disaggregation (for monolayers). Voltage clamp
experiments were controlled and analyzed with an Axopatch 200B
ampliﬁer and pClamp 10.2/Digidata 1440A acquisition system
(Molecular Devices, Sunnyvale, CA, USA) and OriginPro8 software
(OriginLab Corporation, Northampton, MA, USA). Data were ﬁltered at
5 kHz and sampled at 5–20 kHz. Activation curve data were ﬁtted to a
Boltzmann equation, of the form g= gmax / (1 + exp(V1/2− Vm) / k),
where g is the conductance, gmax the maximum conductance, Vm is the
membrane potential, V1/2 is the voltage at which half of the channels
are activated and k is the slope factor. Steady-state inactivation values
were ﬁtted to a Boltzmann equation of the form I= Imax/(1 + exp(V1/
2− Vm)/k), where I is the peak current amplitude, Imax the maximum
peak current amplitude, Vm is the membrane potential, V1/2 is the
voltage at which half of the channels are inactivated, and k is the slope
factor. The sodium current decay after the peak INa was ﬁtted with a
monoexponential function between −40 and −25 mV, and a bi-ex-
ponential function between −20 and 20 mV, from where τ fast and τ
slow were obtained. Both the slow inactivation and the recovery from
inactivation data were ﬁtted to mono-exponential functions, to obtain
their respective time constants.
2.10. Sodium current recordings in tsA201 cells
2.10.1. Site-directed mutagenesis
SCN5A_c.1100G > A was introduced in the wild-type (WT) human
SCN5A cDNA cloned in pcDNA3.1 using the QuikChange Site-Directed
Mutagenesis system (Stratagene, La Jolla, CA, USA). The resultant
construct was directly sequenced to verify the presence of the desired
mutation and the absence of additional variations.
2.10.2. Cell culture and transfection
tsA201 cells were maintained as described previously [19] and
transiently transfected with the vectors encoding for SCN5A
(Nav1.5_WT only, Nav1.5_R367H only, or both WT and R367H vectors),
using Lipofectamine 2000 (Life Technologies).
2.10.3. Electrophysiological studies
Sodium currents were measured at room temperature using the
standard whole cell patch-clamp technique [20] 48 h after transfection.
Voltage clamp experiments were controlled and analyzed as described
for iPS-CM.
2.11. Cell surface protein biotinylation in tsA201 cells
Cells were plated and transfected as above and membrane proteins
were biotinylated and isolated as previously described [19]. Proteins
were resolved in 4% SDS-PAGE gels and transferred to PVDF mem-
branes. Membranes were probed with an anti-human Nav1.5 antibody
(Alomone Labs, Jerusalem, Israel) and a secondary horseradish perox-
idase-conjugated antibody (Thermo Scientiﬁc, Rockford, IL, USA).
Signals were detected with the SuperSignal West Femto Chemilumi-
niscent substrate (Pierce, Thermo Scientiﬁc). A mouse antibody against
Na+/K+ ATPase (Abcam) was used as biotinylation control. Expression
of Nav1.5 was quantiﬁed using ImageJ software (National Institute of
Health, NIH).
2.12. Statistical analysis
Results are presented as mean ± standard error. Statistical com-
parisons were performed using an unpaired Student's t-test or two-way
ANOVA with Bonferroni or Dunnett's post-test for multiple comparisons
as appropriate. Statistical signiﬁcance was deﬁned where p < 0.05.
3. Results
3.1. Generation of iPS cell lines
A male Caucasian patient, aged 69, clinically diagnosed with
Brugada syndrome was identiﬁed through the Familial Arrhythmia
Network for Scotland. He presented with classical ST-segment elevation
in the electrocardiogram (Fig. 1) and was found to have a missense
mutation in SCN5A (c.1100G > A, leading to Nav1.5_p.R367H) in
heterozygosis. This mutation is located in the pore region of the ﬁrst
domain of Nav1.5. We obtained and processed in parallel skin biopsies
from this patient and an age and sex-matched healthy volunteer.
Emerging ﬁbroblasts were reprogrammed using episomal vectors and,
under stem cell selection conditions, possible iPS cell colonies, assessed
based on morphology, appeared after around 20 days. Colonies were
Fig. 1. Clinical manifestation of Brugada syndrome. Partial electrocardiogram of the
proband showing the ST segment elevation characteristic of Brugada syndrome.
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treated as individual clones, manually picked and expanded in feeder-
free conditions to give rise to independent cell lines. Each cell line grew
in ﬂat densely packed colonies with cells exhibiting the high nucleus to
cytoplasm ratio typical for embryonic stem cells (Fig. 2A). Sequencing
of the whole coding region of SCN5A in genomic DNA samples of all cell
lines conﬁrmed the presence of SCN5A_c.1100G > A in the patient
lines, and its absence in the control lines (Fig. 2B). We also identiﬁed 3
synonymous SNVs (rs6599230, rs7430407 and rs1805126) that were
present in all lines.
3.2. Characterization of patient and control iPS cell lines
To verify that the iPS cell lines expressed pluripotency markers,
RNA was extracted from undiﬀerentiated cultures, puriﬁed and reverse
transcribed for each sample in biological triplicate and assessed for the
relative expression of POU5F1 (the gene encoding Oct-4), Sox2, Nanog
and c-Myc (Fig. 2C). One-way ANOVA showed no diﬀerences in ex-
pression of the tested pluripotency transcription factors between pa-
tient and control iPS cell lines. We also ﬁxed and stained un-
diﬀerentiated pluripotent stem cells for the pluripotency markers
Nanog, Oct-4 and Tra-1-60. As expected, both patient and control cell
lines showed nuclear Nanog and Oct-4 staining, and cell surface
staining for Tra-1-60 (Fig. 2D). Diﬀerentiated cells surrounding the
colonies did not stain for pluripotency markers but were visible as DAPI
stained nuclei. Using ﬂow cytometry, we also investigated the percen-
tage of cells expressing the cell surface markers SSEA-3 and SSEA-4 in
undiﬀerentiated populations of patient and control iPS cell lines. No
diﬀerences were observed in the percentage of cells expressing each
marker between patient and control cell lines (Fig. 2E). Additionally,
we analyzed genomic DNA from each iPS cell line for chromosomal
integrity using a single nucleotide polymorphism (SNP) array (Sup-
plemental Table 1). Finally, we generated embryoid bodies (EBs) from
both patient and control derived iPS cell lines and assessed their ability
to diﬀerentiate into all 3 germ layers. EBs spontaneously diﬀerentiated
into cells from endoderm, ectoderm and mesoderm, as evidenced by
immunoﬂuorescence staining for alpha-fetoprotein (AFP), β-tubulin III
and muscle actin (Fig. 2F).
3.3. Morphological characterization of patient and control derived
cardiomyocytes
We induced cardiac diﬀerentiation of iPS cells and obtained cardi-
omyocytes (iPS-CM) which were aggregated in the form of beating
bodies, and contracted spontaneously (Supplemental Videos 1 and 2).
To compare the morphological properties of patient and control iPS-
CM, we enzymatically and mechanically disaggregated 3–4 week old
beating bodies for immunoﬂuorescence staining. Disaggregation re-
sulted in single as well as clusters of beating cardiomyocytes, with
groups of connected cardiomyocytes exhibiting synchronized contrac-
tion. After 3–5 days of recovery, we ﬁxed and stained cells for markers
of the cardiac contractile apparatus (Fig. 3A). Control and patient cells
isolated from beating bodies stained positive for alpha actinin, cardiac
troponin I (cTnI) and cardiac troponin T (cTnT). Single cTnT staining
exhibited the striated pattern of thin ﬁlaments while double staining for
cTnI and alpha actinin resulted in alternating striations, staining thin
ﬁlaments and Z-lines respectively.
We examined the structure of the contractile apparatus of beating
bodies in more detail using transmission electron microscopy. In both
patient and control iPS-CM, myoﬁbrils varied in size with some con-
sisting of a single sarcomere. Some cells contained a greater number of
myoﬁbrils with increased organization, exhibiting some alignment of Z-
lines between adjacent myoﬁbrils (Fig. 3B, left). At high magniﬁcation,
we observed sarcomeres with I-bands and A-bands in addition to Z-lines
(Fig. 3B, right).
3.4. Electrophysiological characterization of patient and control derived
cardiomyocytes
We ﬁrst studied the sodium current properties of patient and control
iPS-CM generated using an embryoid body based diﬀerentiation pro-
tocol. Cardiomyocytes were derived from two diﬀerent patient iPS cell
clones. Two separate diﬀerentiations for each clone were used for our
Fig. 2. Control and patient-speciﬁc iPS cell lines express
pluripotency markers. (A) Representative light microscopy
images of healthy control (left) and patient (right) newly
derived induced pluripotent stem (iPS) cells in feeder-free
culture. Scale bars represent 1000 μm. (B) The missense
mutation SCN5A_c.1100G > A was identiﬁed in genomic
DNA isolated from patient (right) but not healthy control
derived iPS cells (left). (C) The relative expression of
pluripotency transcription factors Oct-4, Sox2, Nanog and
c-Myc in undiﬀerentiated cells is shown as mean values of
biological triplicates± SEM. (D) Representative merged
images of undiﬀerentiated iPS cells showing positive
staining for pluripotency markers Nanog, Oct-4 and Tra-1-
60 for both control (upper panels) and patient (lower pa-
nels) iPS cells. Nuclei were counterstained with DAPI
(blue). Scale bars represent 100 μm. (E) The percentage of
SSEA-3 and SSEA-4 positive cells in undiﬀerentiated iPS
cell cultures is given as the mean of at least three in-
dependent wells ± SEM (F) Embryoid bodies (EBs) were
formed from undiﬀerentiated iPS cells and diﬀerentiated in
suspension for 7 days and for an additional 10 days adhered
to plates. Control (upper panels) and patient (lower panels)
derived EBs showed positive staining for all three germ
layers endoderm (AFP), ectoderm (β-tubulin III) and me-
soderm (muscle actin). Nuclei were counterstained with
DAPI (blue). Scale bars represent 100 μm.
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study. All these iPS-CM were characterized independently. The sodium
current properties of each of the lines were compared to the results
obtained from cardiomyocytes derived from one control iPS cell line.
Since the results obtained for the two diﬀerentiations per clone and for
the two patient iPS-CM clones were very similar, data was pooled.
Whole cell current recordings showed a loss of function of the sodium
channel current in patient-derived compared to control-derived cardi-
omyocytes. Representative examples of INa traces for patient and con-
trol cardiomyocytes at varying potentials are shown in Fig. 4A. Peak INa
density was reduced by 45.5% in patient-derived compared to control-
derived cardiomyocytes (p < 0.05, Fig. 4B, Table 1). In addition,
voltage-activation data ﬁt to a Boltzmann equation revealed a positive
7.42 mV shift of the V1/2 in patient respect to control cells, without
signiﬁcant changes in the slope factor (Fig. 4C, Table 1). Steady-state
voltage dependence of inactivation data ﬁt to a Boltzmann equation
evidenced a negative shift of 8.51 mV of the V1/2 in patient respect to
control cells, and no signiﬁcant changes in the slope factor (Fig. 4C,
Table 1). Analysis of recovery from inactivation time course is illu-
strated in Fig. 4D. Data was ﬁtted with a bi-exponential function and
revealed a faster recovery in the patient cells (Table 1).
In a second set of experiments, we studied the sodium current
properties of patient and control iPS-CM generated using a monolayer-
based diﬀerentiation protocol. For these experiments, we used one of
the patient iPS cell lines and an additional healthy control iPS cell line
(Supplemental Videos 3 and 4). Whole cell current recordings showed a
loss of function of the sodium channel current in patient-derived
compared to control-derived cardiomyocytes. Examples of INa traces are
depicted in Supplemental Fig. 1A. Analysis of the data revealed a re-
duction of 33.12% in peak current density in the patient-derived
compared to control-derived iPS-CM (p < 0.05; Supplemental Fig. 1B
and Table 1). It is worth noting that this analysis shows an under-
estimation of the current reduction since 6 out of 17 control cells dis-
played currents too large to allow proper voltage control in our already
low sodium recording conditions. Furthermore, we observed a positive
7.53 mV shift in the activation V1/2, and a negative 5.89 mV shift in the
steady-state inactivation V1/2 in patient respect to control cells
(p < 0.001 and p < 0.01, respectively; Supplemental Fig. 1C and
Table 1). As in the ﬁrst set of experiments, we observed a faster re-
covery from inactivation in the patient iPS-CM respect to control
(p < 0.05, Supplemental Fig. 1D and Table 1).
3.5. Electrophysiology and cell surface protein biotinylation in tsA201 cells
It is worth noting that the available studies of Nav1.5_p.R367H had
been performed in a homozygous state for either the WT or the mutant
gene (WT/WT or R367H/R367H). They showed a total loss of INa when
only mutant channels were expressed, both in HEK293 cells and in
Xenopus oocytes. Conversely, our patient carried the mutant channel in
a heterozygous state (WT/R367H), and our results in iPS-CM showed
diﬀerences in the biophysical properties of the current obtained in the
patient compared to the control cells. This prompted us to study the
biophysical properties of the sodium current in tsA201 cells transiently
expressing sodium channels in heterozygous conditions. In contrast
with the iPS-CM, in this setting the only diﬀerence between cells would
be the point mutation of interest.
We transfected tsA201 cells with either the vector encoding
Nav1.5_WT (homozygous WT cells), the vector encoding Nav1.5_R367H
(homozygous R367H cells) or both vectors (heterozygous WT/R367H
cells). We performed the electrophysiological recordings on isolated
cells 48 h after transfection using whole cell patch-clamping and
normal sodium bath solution. Representative examples of INa traces for
the 3 conditions are shown in Fig. 5A. Recordings performed in cells
transfected with only Nav1.5_R367H revealed a complete loss of current
(Fig. 5A, lower panel). Peak INa density was signiﬁcantly reduced by
49.8% in heterozygous WT/R367H cells with respect to homozygous
WT/WT cells (Fig. 5B). No further changes in V1/2 were observed after
data ﬁtting in either activation or steady-state inactivation (Fig. 5C,
Table 2) or in the recovery from inactivation time course (Fig. 5D,
Table 2).
Previous immunoﬂuorescence assays of Nav1.5_p.R367H expressed
in HEK293 cells had shown that the mutant channels could reach the
plasma membrane [14]. To quantify whether the WT and mutant
channels localized at the cell surface in similar amounts, we performed
protein biotinylation assays in tsA201 cells. Fig. 5E and F show that the
cell surface Nav1.5 expression was similar in homozygous Nav1.5_WT
cells, homozygous Nav1.5_R367H cells and heterozygous WT/R367H
cells. Therefore, the p.R367H Nav1.5 channels could traﬃc eﬃciently
to the plasma membrane, and did not interfere in WT channel traf-
ﬁcking.
4. Discussion
Sodium channel current loss of function has been long and widely
accepted as a hallmark of Brugada syndrome. Still, most of the evidence
comes from heterologous expression studies. To date, only two studies
have shown evidence for the association of a sodium channel mutation
with either Brugada syndrome or overlapped LQT3/Brugada syndrome
in iPS-CM [8,9]. However, these studies only show a reduction in
Fig. 3. Control and patient-speciﬁc iPS-CM show typical patterns for cardiac markers. (A)
Control (top panels) and patient (bottom panels) iPS-CM stained positive for alpha actinin
and cardiac Troponin I (left), and cardiac Troponin T (right), showing intact myoﬁbrils.
Nuclei were counterstained with DAPI (blue). Figure shows representative merged
images. Scale bars represent 20 μm. (B) Control (top panels) and patient (bottom panels)
iPS-CM showed mitochondria (Mito) and lipid deposits (Lipid) as well as myoﬁbrils (MF)
of varying width and length (left). We also observed sarcomeres with I bands (I) and A
bands (A) in addition to Z lines (Z) (right). Scale bars represent 1 μm.
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sodium current density in patient iPS-CM compared to the control iPS-
CM. Thus, our present study is the ﬁrst to show the loss of sodium
channel function by a complete characterization of the sodium current
properties in native cells from a BrS patient who carries a mutation in
SCN5A. Although expected, it is not trivial to show in native cells that a
mutation that causes total loss of function of the current provokes a
reduction of the total current to 50%. In fact, we identiﬁed in the iPS-
CM further pro-arrhythmic changes in channel function that could not
be detected using conventional heterologous expression systems. It is to
note that a comparison of the eﬀects of SCN5A mutations on sodium
current properties in both model systems had never been performed
before for Brugada syndrome.
We successfully generated iPS cells through reprogramming of
dermal ﬁbroblasts from a Brugada syndrome patient and an age and
sex-matched healthy volunteer. No diﬀerences were observed between
patient and control iPS cell lines in terms of colony morphology,
Fig. 4. Patient-speciﬁc iPS-CM display altered INa properties.
Filled symbols are used to depict data for healthy control iPS-
CM and open symbols represent values for patient-speciﬁc
cardiomyocytes. Values are expressed as mean ± SEM. (A)
Representative whole cell sodium current traces recorded
from control and patient-speciﬁc cells. Currents were elicited
by depolarizing potentials as shown in the inset. Traces for
pulses from −50 mV to −15 mV are shown. (B) Current-
voltage (I–V) relationship. INa amplitude was normalized to
the cell capacitance to obtain current density (INa density)
values. Experimental points represent the peak-amplitude of
INa density at each given voltage. (C) INa voltage-dependence
of activation and steady-state inactivation for control and
patient cells. Conductance values for the activation curve
were obtained from the peak current values taken from the
I–V relationship. Symbols represent experimental data
plotted against the given depolarizing voltage values. Steady-
state inactivation protocol is shown in the inset on the left.
Symbols represent experimental data plotted against pre-
conditioning pulse values. Solid lines represent the
Boltzmann ﬁt of the experimental points. (D) Recovery from
inactivation properties were studied by applying the double
pulse protocol shown in the inset. A 50 ms depolarizing pulse
to −20 mV (P1) was followed by a hyperpolarizing pulse to
−120 mV of increasing duration (1–40 ms), that preceded a
test pulse to −20 mV (P2). The P2/P1 ratio values plotted
against the recovery interval times were ﬁtted to bi-ex-
ponential functions (solid lines).
Table 1
Biophysical parameters of WT and mutant channels in iPS-CM.










pA/pF −78.77 ± 5.16 −42.93 ± 3.86⁎⁎⁎ −45.62 ± 5.37 −30.51 ± 3.09⁎
n 3 7 11 13
Activation
V1/2 (mV) −44.15 ± 0.37 −36.73 ± 0.32⁎⁎⁎ −32.96 ± 0.79 −25.44 ± 0.78⁎⁎⁎
k 5.57 ± 0.33 5.86 ± 0.28 3.94 ± 0.14 5.58 ± 0.26⁎⁎⁎
n 3 7 11 13
Steady-state inactivation
V1/2 (mV) −61.64 ± 0.77 −70.15 ± 2.76⁎ −48.80 ± 0.79 −54.69 ± 1.21⁎⁎
k 8.94 ± 1.54 8.70 ± 0.57 6.70 ± 0.33 9.59 ± 0.24⁎⁎⁎
n 3 7 8 10
Recovery from inactivation
τ (ms) τf: 5.85 ± 1.01
τs: 40.38 ± 4.95
τf: 2.89 ± 0.35⁎⁎
τs: 34.45 ± 14.45
τf: 2.58 ± 0.31
τs: 46.17 ± 7.01
τf: 1.68 ± 0.18⁎
τs: 20.12 ± 6.76⁎
n 3 6 5 5
Activation and steady-state inactivation parameters were calculated by data ﬁtting to Boltzmann functions (see Materials and methods). V1/2 is the voltage for half-maximal activation or
steady-state inactivation, k is the slope factor and n the number of cells. Recovery from inactivation data was ﬁtted to a bi-exponential function (see Materials and methods) to obtain the
fast and slow time constants (τf and τs, respectively). Values are expressed as mean ± SEM.
⁎ p < 0.05.
⁎⁎ p < 0.01.
⁎⁎⁎ p < 0.001.
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expression of pluripotency transcription factors and proteins, or their
ability to diﬀerentiate into the three germ layers. As anticipated, the
only diﬀerence was the presence of the patient's mutation
(SCN5A_c.1100G > A) in the patient-speciﬁc iPS cell lines and its ab-
sence in those obtained from the healthy volunteer.
Comparison of ultrastructure and staining for markers of the cardiac
contractile apparatus did not show any obvious diﬀerences between
cardiomyocytes derived from patient-speciﬁc and healthy control
pluripotent stem cells. Importantly, the analysis of electrophysiological
recordings revealed a 33.1–45.5% reduction of peak INa density in pa-
tient-derived compared to healthy control-derived cardiomyocytes.
This decrease represents a loss of function of the sodium channel.
Previous ﬁndings had shown a complete loss of function of homozygous
Nav1.5_R367H channels [10–13]. In heterozygous conditions, a reduc-
tion of INa to 50%, most likely originated only from the expression of
the WT allele, would be expected. This is consistent with reduced peak
INa density that we observed in the patient iPS-CM. Surprisingly, our
iPS-CM model showed additional changes in other electrophysiological
properties. We observed a positive shift in the voltage-dependence of
activation and a negative shift in the voltage-dependence of steady-
state inactivation in the patient-speciﬁc cardiomyocytes. These voltage-
dependence changes further contribute to the loss of function of the
sodium channel. We also detected a faster recovery from channel in-
activation in the patient iPS-CM. This acceleration in channel recovery
has been proposed to contribute to the generation of arrhythmias in
Brugada syndrome patients [21]. Importantly, we observed similar
changes in sodium current properties when comparing patient and
control iPS-CM generated with two distinct diﬀerentiation protocols.
Although the diﬀerences in the current between patient and control iPS-
CM were qualitatively the same in both experimental sets, the magni-
tude of the eﬀects was diﬀerent. This variability is expected considering
that iPS-CM were obtained by diﬀerent protocols. Moreover, the control
iPS-CM used in both protocols were from two non-related healthy in-
dividuals. The results obtained support the idea that I) the SNV under
study has an eﬀect on sodium current properties; and II) the individual-
speciﬁc genetic background could modulate the magnitude of this
Fig. 5. Nav1.5_R367H markedly decreases peak INa. (A)
Representative whole cell sodium current traces recorded
from WT, WT/R367H and R367H cells. Currents were eli-
cited by depolarizing potentials as shown in the inset. Traces
for pulses from−60 mV to −5 mV are shown. (B–D) Filled
symbols are used to depict data for WT cells, and open
symbols represent values for WT/R367H cells. Values are
expressed as mean ± SEM. (B) Current-voltage (I–V) re-
lationship. INa amplitude was normalized to the cell capa-
citance to obtain current density (INa density) values.
Experimental points represent the peak-amplitude of INa
density at each given voltage. (C) INa voltage-dependence of
activation and steady-state inactivation for WT and WT/
R367H cells. Conductance values for the activation curve
were obtained from the peak current values taken from the
I–V relationship. Symbols represent experimental data
plotted against the given depolarizing voltage values.
Steady-state inactivation protocol is shown in the inset on
the left. Symbols represent experimental data plotted against
preconditioning pulse values. Solid lines represent the
Boltzmann ﬁt of the experimental points. (D) Recovery from
inactivation properties were studied by applying the double
pulse protocol shown in the inset. A 50 ms depolarizing
pulse to −20 mV (P1) was followed by a hyperpolarizing
pulse to −120 mV of increasing duration (1–40 ms), that
preceded a test pulse to −20 mV (P2). The P2/P1 ratio va-
lues plotted against the recovery interval times were ﬁtted to
mono-exponential functions (solid lines). (E) Representative
image of western blot detection of Nav1.5 and Na+/K+
ATPase proteins performed after cell surface biotinylation of
non-transfected cells (NT), cells transfected only with the
vector encoding Nav1.5_WT (WT), with the vectors encoding
Nav1.5_WT and Nav1.5_R367H (WT/R367H) and only with
the vector encoding Nav1.5_R367H (R367H). (F) Scatter plot
showing the relative surface Nav1.5 protein expression.
Intensity values were calculated as described in Methods and
normalized relative protein expression was plotted for each
of the replicates (dots). Lines represent means ± SEM.
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eﬀect.
In support to our experimental data, we provide a comparison of the
INa parameters reported here with those previously published for em-
bryonic stem cell-derived cardiomyocytes (ES-CM), iPS-CM and native
cardiomyocytes (Table 3). It is worth noting that the voltage for INa
half-maximal activation that we recorded in our control cells is similar
to that reported for native human cardiomyocyte preparations [22–27]
(Table 3). Our value for EB-diﬀerentiated cardiomyocytes was even
closer to that for native cells than that of other human iPS [28–30] and
ES [31,32] cell derived cardiomyocytes. Regarding half-maximal
steady-state inactivation voltage, the value reported for native pre-
parations is clearly more hyperpolarized (by approx. 19 mV) than the
one recorded in ES-CM, and this diﬀerence increases up to 33 mV when
compared with that for iPS-CM. However, the values obtained in this
study are in line with those reported for other iPS-CM (Table 3).
Our cell surface protein biotinylation studies in tsA201 cells de-
monstrate that both WT and mutant channels reach the cell surface to a
similar extent when Nav1.5_R367H is expressed either in heterozygosis
or homozygosis. Thus, the corresponding partial or total INa reduction
would result from a mutant non-functional channel rather than by a
traﬃcking defect, in agreement with previous studies [14]. Due to the
limited amount of tissue available from iPS-CM, we could not perform
biotinylation studies with these cells. However, based on our results
from tsA201 cells, a traﬃcking defect in iPS-CM caused by the mutation
would be unlikely. Consequently, these results argue against a negative
dominant eﬀect of p.R367H as it has been shown for other mutations in
Nav1.5 [33,34].
Nevertheless, a functional interaction between sodium channel
alpha subunits could account for the diﬀerences in voltage-dependent
and kinetic properties of the sodium current that we observed between
patient and control iPS-CM. Indeed, recent structural studies of the
Nav1.5 channel have shown evidence for the formation of asymmetric
α-subunit dimers [35]. The authors propose that the dimerization of the
α subunits would be mediated through the binding of calmodulin to
their C-terminus. The mutation studied in the present study (p.R367H)
is far from the C-terminus of the sodium channel, and thus would not be
expected to interfere with dimerization. However, if as proposed,
functional Nav channels do exist in oligomeric states involving at least
two α subunits, functional interactions between WT and mutant α
subunits could explain the kinetic and voltage dependent diﬀerences in
patient-speciﬁc iPS-CM compared to control. We did not observe such
diﬀerences in current properties in tsA201 cells. This might be due to
unbalanced amounts of endogenous calmodulin or other sodium
channel modulatory molecules, and the overexpressed Nav1.5 in tsA201
cells. Conversely, iPS-CM are likely to possess the molecular machinery
to allow Nav1.5 oligomerization. Thus, the formation of heterodimers
(WT/R367H) could account for the diﬀerences in INa observed between
the patient and control iPS-CM.
Overall, the two cellular models studied in this work present im-
portant diﬀerences. It should be considered that the experimental
conditions for tsA201 cells (homozygous WT/WT vs. heterozygous WT/
mutant) only diﬀer in the transfected gene. On the other hand, the
patient and the control iPS-CM are likely to carry variations in their
genetic background in addition to the patient's mutation. Some of these
variations could aﬀect cardiac-speciﬁc proteins (e.g. channel auxiliary
subunits) which are not expressed in tsA201 cells. These variations,
either common or rare, could inﬂuence the sodium current's biophysical
properties. Altogether, our work points to these diﬀerences as a possible
explanation of why electrophysiological changes other than reduced
peak INa were evident only when analyzing iPS-CM but not in the
heterologous tsA201 cell model.
Our results suggest that the patient-speciﬁc genetic background
could be a critical determinant of the phenotypical manifestation of
Brugada syndrome. Finally, our work highlights the need of assessing
the pathophysiological mechanisms of sodium channel mutations in a
cardiac- and patient-speciﬁc model.
5. Study limitations
Our results illustrate the ability of patient-speciﬁc iPS cell tech-
nology to model the abnormal functional phenotype of Brugada syn-
drome. Nevertheless, an issue still remains, which is the maturity of the
obtained iPS-CM. Although cardiomyocytes derived from iPS cells
usually represent a mixture of cells with diﬀerent degrees of maturity, it
has been demonstrated that human iPS-CM have all major cardiac ionic
Table 2






pA/pF −84.62 ± 11.24 −42.48 ± 3.46⁎⁎
n 11 10
Activation
V1/2 (mV) −33.91 ± 0.20 −32.42 ± 0.22
k 6.54 ± 0.18 6.63 ± 0.20
n 11 10
Steady-state inactivation
V1/2 (mV) −71.03 ± 0.25 −72.36 ± 0.32
k 10.17 ± 0.23 10.18 ± 0.29
n 11 6
Recovery from inactivation
τ (ms) 5.80 ± 0.17 5.93 ± 0.23
n 6 4
Activation and steady-state inactivation parameters were calculated by data ﬁtting to
Boltzmann functions (see Materials and methods). V1/2 is the voltage for half-maximal
activation or steady-state inactivation, k is the slope factor and n the number of cells.
Recovery from inactivation data was ﬁtted to a mono-exponential function to obtain the
time constant τ. Values are expressed as mean ± SEM.
⁎⁎ p < 0.01.
Table 3
Comparison of INa voltage-dependent properties.





−44.15 ± 0.37 (n= 3) −61.48 ± 0.5 (n= 3)
Monolayer-based
diﬀerentiation
−32.96 ± 0.79 (n= 11) −48.80 ± 0.79 (n= 8)
iPS-CM
Ma et al. [28] −34.1 (n= 5) −72.1 (n= 5)
Ma et al. [29] −39.68 ± 1.96 (n= 8) −44.63 ± 5.77 (n= 8)
Terrenoire et al.
[30]
−25 ± 0.3 (n= 3) −70.3 ± 1.7 (n= 3)
Terrenoire et al.
[30]
−68.9 ± 0.9 (n= 6)
ES-CM
Satin et al. [31] −30 (n= 21) −72.6 ± 0.7 (n= 19)





−38.9 ± 0.9 (n= 46) −95.8 ± 0.9 (n= 46)
Sakakibara et al.
[27]
−42.3 ± 1.7 (n= 12) −99.8 ± 2.1 (n= 12)
Sakakibara et al.
[27]
−43.8 ± 0.2 (n= 10) −94.5 ± 2.3 (n= 10)
Feng et al. [26] −38.6 ± 2.9 (n= 6) −95.1 ± 5.4 (n= 6)
Valdivia et al. [24] −51 ± 1.0 (n= 11) −102 ± 16 (n= 3)
Valdivia et al. [24] −50 ± 1.1 (n= 17) −88 ± 1.9 (n= 10)
Barajas-Martínez
et al. [25]
~−52 −90.1 ± 0.9 (n= 3)
Jia et al. [22] −93 (n= 5)
The table shows the voltage for half-maximal activation and inactivation for control cells
in each category. Values are expressed as mean ± SD or SEM, as reported in each ori-
ginal study (if available). The number of cells characterized in each work is provided (n).
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currents, including INa, ICa-L, If, Ito, IK1, IKr, IKs and IK,ATP [28,36,37] and
would thus be suitable for examining ion channel function in a patient-
speciﬁc context. In this sense, we have shown that the cardiomyocytes
obtained from our patient and control exhibit typical cardiac markers
and have functional cardiac sodium channels. Therefore, our results
support the accepted current idea that the relative immaturity of iPS-
CM does not prevent their use as an accurate system to model chan-
nelopathies aﬀecting Nav1.5. Nevertheless, due to this limitation, we
focused our studies on the sodium current since this is less subject to
cell variability than action potentials.
It is important to acknowledge that we cannot generalize our results
to other sodium channel mutations. Thus, at the moment our conclu-
sions should be limited to the speciﬁc variant studied in this work.
Nonetheless, we believe that our ﬁndings represent important evidence
on how the cellular environment may contribute to the phenotypical
expression of a sodium channel mutation.
6. Conclusions
Cardiomyocytes derived from iPS cells from a Brugada syndrome
patient with a mutation in SCN5A recapitulate the loss of function of
the sodium channel current associated with this syndrome, including
pro-arrhythmic changes in channel function that could only be detected
using iPS-CM and not in conventional heterologous expression systems.
We believe that our ﬁndings underscore the extra value that the use of
patient-speciﬁc iPS-CM confers to mutation studies in BrS. Therefore,
we expect that our work will contribute to establish iPS-CM as an
adequate cell model for the investigation of BrS.
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